Granules India Ltd News
Granules surges 18% in 1 month; why pharma stock hits 52-week high today?
Granules India plans to raise up to ₹1,762 crore from promoter, and non-promoter groups through a mix of convertible warrants and preferential issue of equity shares.
 "Granules surges 18% in 1 month; why pharma stock hits 52-week high today?")
Granules India gets approval from USFDA for generic ADHD medication
Drug firm Granules India on Monday said it has received approval from the US health regulator to market a generic medication for attention deficit hyperactivity disorder. Granules Pharmaceuticals Inc, a wholly-owned subsidiary of the company, has received tentative approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Amphetamine extended-release orally disintegrating tablets in multiple strengths, the company said in a statement. The company's product is the generic equivalent of Adzenys XR-ODT, it added. The product will be manufactured at Granules' US-based facility located in Chantilly, Virginia. The medication is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and has an estimated market size of around USD 172 million according to IQVIA (IMS Health). Currently, the market has only one approved generic and one authorised generic, positioning Granules favourably to expand access to this crit
Stocks to Watch today, Dec 22: Granules, Infosys, Tata Steel
Stocks to Watch today, Dec 22: Varun Beverages, KEC International, PVR Inox, Rites, Tech M, and Crompton Greaves are some of the other stocks to watch today
 "Stocks to Watch today, Dec 22: Granules, Infosys, Tata Steel")
These 3 stocks are a must-have in your portfolio; key reasons inside
Avanti Feeds is showing a strong bullish setup on the daily chart, with price sustaining above its 20, 50, 100 and 200-day EMAs, confirming a medium- to long-term trend reversal in favour of bulls.
 "These 3 stocks are a must-have in your portfolio; key reasons inside")
Lupin, Granules: Which pharma stocks to buy, sell amid US tariff flip-flop?
Technical charts show that select pharma stocks are trading with a negative bias and can tumble up to 19% from here. Granules India, however, looks strong on chart and can rally up to 19%.
 "Lupin, Granules: Which pharma stocks to buy, sell amid US tariff flip-flop?")
Nifty Pharma down 1.5%: Granules, Biocon lead with over 2% fall; Here's why
Pharma stocks fell after Trump said tariffs will be imposed within a week, rising up to 250 per cent in 12-18 months
 "Nifty Pharma down 1.5%: Granules, Biocon lead with over 2% fall; Here's why")
Dr Reddy's Labs, Lupin: Nifty Pharma slips 2% amid Trump tariff jitters
Nifty Pharma index declined 1.5 per cent in trade after US President Donald Trump warned to impose a 25 per cent tariff on Indian goods starting August 1
 "Dr Reddy's Labs, Lupin: Nifty Pharma slips 2% amid Trump tariff jitters")
